Bristol Abilify “Approvable” For Bipolar Acute Mania
This article was originally published in The Pink Sheet Daily
Bristol-Myers Squibb/Otsuka's Abilify (aripiprazole) is "approvable" for the treatment of acute mania in bipolar disorder, Bristol said during its first quarter earnings call April 28
You may also be interested in...
FDA clears aripiprazole for the treatment of acute manic and mixed episodes associated with bipolar disorder. The approval places Abilify labeling on par with other atypical antipsychotics.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.